Geneos Therapeutics: Raises $17M in Series A2 Funding

Geneos Therapeutics Raises $17M in Series A2 Funding

• Geneos Therapeutics, a Plymouth Meeting, PA-based clinical stage biotherapeutics company, raised $17M in Series A2 funding
• The round was led by Flerie Invest with participation from Santé Ventures, Korea Investment Partners, Global Bio Fund, and INOVIO Pharmaceuticals
• In conjunction with the financing, Dr. Ted Fjällman, Partner, Flerie Invest joined Geneos’ Board of Directors
• The company intends to use the funds to expand the GT-30 Phase Ib/IIa clinical trial, its pipeline into a new indication, and continued operations
• GeneosTherapeutics is a clinical stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies
• The platform allows Geneos to develop personalized therapies tailored to each patient’s unique tumor mutations